Article info

Download PDFPDF

Extended report
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Authors

  1. Correspondence to Professor Won Park, IN-HA University, School of Medicine, Medicine/Rheumatology, 366, Seohae-Daero, Jung-Gu, Incheon 22332, Republic of Korea; parkwon{at}inha.ac.kr and Professor Dae Hyun Yoo, Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni-Ro, Seongdong-Gu, Seoul 04763, Republic of Korea; dhyoo{at}hanyang.ac.kr
View Full Text

Citation

Yoo DH, Prodanovic N, Jaworski J, et al
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Publication history

  • Received October 17, 2015
  • Revised April 7, 2016
  • Accepted April 9, 2016
  • First published April 29, 2016.
Online issue publication 
January 10, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.